177 related articles for article (PubMed ID: 34175983)
1. Adenosine A
Marques TR; Natesan S; Rabiner EA; Searle GE; Gunn R; Howes OD; Kapur S
Psychopharmacology (Berl); 2022 Nov; 239(11):3439-3445. PubMed ID: 34175983
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Evaluation and Quantification of
Khanapur S; van Waarde A; Dierckx RA; Elsinga PH; Koole MJ
J Nucl Med; 2017 Mar; 58(3):466-472. PubMed ID: 27789720
[TBL] [Abstract][Full Text] [Related]
3. Impact of an Adenosine A
Prasad K; de Vries EFJ; Sijbesma JWA; Garcia-Varela L; Vazquez-Matias DA; Moraga-Amaro R; Willemsen ATM; Dierckx RAJO; van Waarde A
Mol Pharm; 2022 Aug; 19(8):2992-3001. PubMed ID: 35849844
[TBL] [Abstract][Full Text] [Related]
4. Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease.
Ramlackhansingh AF; Bose SK; Ahmed I; Turkheimer FE; Pavese N; Brooks DJ
Neurology; 2011 May; 76(21):1811-6. PubMed ID: 21606452
[TBL] [Abstract][Full Text] [Related]
5. Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment.
Urigüen L; García-Fuster MJ; Callado LF; Morentin B; La Harpe R; Casadó V; Lluis C; Franco R; García-Sevilla JA; Meana JJ
Psychopharmacology (Berl); 2009 Oct; 206(2):313-24. PubMed ID: 19652957
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of dopamine D
Sakayori T; Tateno A; Arakawa R; Kim WC; Okubo Y
Psychopharmacology (Berl); 2021 May; 238(5):1343-1350. PubMed ID: 33180175
[TBL] [Abstract][Full Text] [Related]
7. In vivo 5-HT
Radhakrishnan R; Matuskey D; Nabulsi N; Gaiser E; Gallezot JD; Henry S; Planeta B; Lin SF; Ropchan J; Huang Y; Carson RE; D'Souza DC
Psychiatry Res Neuroimaging; 2020 Jan; 295():111007. PubMed ID: 31760336
[TBL] [Abstract][Full Text] [Related]
8. The relationship between excitement symptom severity and extrastriatal dopamine D
Joo YH; Kim JH; Son YD; Kim HK; Shin YJ; Lee SY; Kim JH
Eur Arch Psychiatry Clin Neurosci; 2018 Sep; 268(6):529-540. PubMed ID: 28623450
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.
Mamo D; Graff A; Mizrahi R; Shammi CM; Romeyer F; Kapur S
Am J Psychiatry; 2007 Sep; 164(9):1411-7. PubMed ID: 17728427
[TBL] [Abstract][Full Text] [Related]
10. The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study With [11C]-(+)-PHNO.
Graff-Guerrero A; Mamo D; Shammi CM; Mizrahi R; Marcon H; Barsoum P; Rusjan P; Houle S; Wilson AA; Kapur S
Arch Gen Psychiatry; 2009 Jun; 66(6):606-15. PubMed ID: 19487625
[TBL] [Abstract][Full Text] [Related]
11. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO.
Girgis RR; Slifstein M; D'Souza D; Lee Y; Periclou A; Ghahramani P; Laszlovszky I; Durgam S; Adham N; Nabulsi N; Huang Y; Carson RE; Kiss B; Kapás M; Abi-Dargham A; Rakhit A
Psychopharmacology (Berl); 2016 Oct; 233(19-20):3503-12. PubMed ID: 27525990
[TBL] [Abstract][Full Text] [Related]
12. Antagonistic interaction between adenosine A2A receptors and dopamine D2 receptors in the ventral striopallidal system. Implications for the treatment of schizophrenia.
Ferré S; O'Connor WT; Snaprud P; Ungerstedt U; Fuxe K
Neuroscience; 1994 Dec; 63(3):765-73. PubMed ID: 7898676
[TBL] [Abstract][Full Text] [Related]
13. In Vivo Evaluation of
Zhou X; Boellaard R; Ishiwata K; Sakata M; Dierckx RAJO; de Jong JR; Nishiyama S; Ohba H; Tsukada H; de Vries EFJ; Elsinga PH
J Nucl Med; 2017 May; 58(5):762-767. PubMed ID: 28062599
[No Abstract] [Full Text] [Related]
14. Binding of the D3-preferring antipsychotic candidate F17464 to dopamine D3 and D2 receptors: a PET study in healthy subjects with [
Slifstein M; Abi-Dargham A; Girgis RR; Suckow RF; Cooper TB; Divgi CR; Sokoloff P; Leriche L; Carberry P; Oya S; Joseph SK; Guiraud M; Montagne A; Brunner V; Gaudoux F; Tonner F
Psychopharmacology (Berl); 2020 Feb; 237(2):519-527. PubMed ID: 31773210
[TBL] [Abstract][Full Text] [Related]
15. In vivo imaging of adenosine A2A receptors in rat and primate brain using [11C]SCH442416.
Moresco RM; Todde S; Belloli S; Simonelli P; Panzacchi A; Rigamonti M; Galli-Kienle M; Fazio F
Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):405-13. PubMed ID: 15549298
[TBL] [Abstract][Full Text] [Related]
16. Adenosine A
Waggan I; Rissanen E; Tuisku J; Joutsa J; Helin S; Parkkola R; Rinne JO; Airas L
J Neurol; 2023 Jan; 270(1):300-310. PubMed ID: 36053386
[TBL] [Abstract][Full Text] [Related]
17. Allosteric Interactions between Adenosine A
Prasad K; de Vries EFJ; Elsinga PH; Dierckx RAJO; van Waarde A
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33572077
[TBL] [Abstract][Full Text] [Related]
18. Multiple Adenosine-Dopamine (A2A-D2 Like) Heteroreceptor Complexes in the Brain and Their Role in Schizophrenia.
Borroto-Escuela DO; Ferraro L; Narvaez M; Tanganelli S; Beggiato S; Liu F; Rivera A; Fuxe K
Cells; 2020 Apr; 9(5):. PubMed ID: 32349279
[TBL] [Abstract][Full Text] [Related]
19. First visualization of adenosine A(2A) receptors in the human brain by positron emission tomography with [11C]TMSX.
Ishiwata K; Mishina M; Kimura Y; Oda K; Sasaki T; Ishii K
Synapse; 2005 Feb; 55(2):133-6. PubMed ID: 15543628
[TBL] [Abstract][Full Text] [Related]
20. Occupancy of adenosine A
Ishibashi K; Miura Y; Wagatsuma K; Toyohara J; Ishiwata K; Ishii K
Neuropharmacology; 2018 Dec; 143():106-112. PubMed ID: 30253174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
